Blackstone, Novartis spin out cardiovascular newco Anthos
By Mark Zipkin | Mar 1, 2019 | 8:11 PM GMT
Leading its first deal since acquiring Clarus Ventures, Blackstone has partnered with Novartis AG (NYSE:NVS; SIX:NOVN) to launch Anthos Therapeutics Inc. (Cambridge, Mass.) with $250 million and Novartis antithrombotic MAA868.
In exchange for
Read the full 324 word article
User Sign In
This article may not be distributed to non-subscribers
PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD